Clinical trialObsRecruiting
Activation of Biobank Registry for Bilio-pancreatic Diseases
Activation of Biobank for Association Study Between Environmental and Genetic Factors in Inflammatory, Functional and Neoplastic Bilio-pancreatic Diseases
- Outcome
- Ongoing
- Phase
- Obs
- Status
- Recruiting
- Study type
- Observational
- Start
- 9 June 2021
- Expected end
- 31 December 2030
- Enrollment
- 2,000 participants
- Sites
- 1
- Primary outcomes
- The rate of patients with each pancreatic disorder presenting with certain exposures or certain biomarkers
- Sponsor
- Other
- Results posted
- No
- Last update
- 8 September 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of establishing the biobank is to create a collection of biological material and clinical data, with a prospective and retrospective mold, in order to investigate the role of genetic predisposition in multifactorial bilio-pancreatic diseases, so that an evaluation of the possible association in the pathogenesis of exogenous factors with endogenous factors can be allowed. Multifactorial diseases are in fact an expression of genetic predisposition upon which one or more environmental stimuli act. Usually the aforementioned factors are not capable individually of triggering disease but, when simultaneously present, can cause the pathological phenotype. Therefore, it becomes important in the description of disease pathogenesis to identify as many risk factors for disease prevention and early diagnosis.
Detailed description public domain (ClinicalTrials.gov)
Samples collected depending on the disease: * Peripheral blood; * Portal blood; * Saliva; * Urine; * Stool; * Cystic fluid; * Pancreatic juice; * Biopsy tissue specimens;